| Case No. |
Age (yrs) |
Duration of Illness (months) |
BIRADS Score |
Histopathological Diagnosis |
Immunohistochemical Markers |
Treatment Modalities |
Clinical Outcomes |
| 1 |
54 |
12 |
4a |
Adenoid cystic carcinoma |
Positive: GATA3, CK7, CD117, CK5/6, p63; Negative: ER, PR, HER2 |
Lumpectomy + adjuvant radiotherapy |
Disease-free at 17 months |
| 2 |
62 |
36 |
4c |
Adenoid cystic carcinoma |
Positive: CK7, CD117, p63; Negative: ER, PR, HER2 |
BCS + adjuvant radiotherapy |
Disease-free at 12 months |
| 3 |
49 |
7 |
4c |
Mixed ductal neuroendocrine carcinoma |
Positive: AE1/AE3, p53, synaptophysin, CD56, high Ki67 index; Negative: ER, PR, HER2 |
MRM + chemoradiation |
Disease-free at 24 months |
| 4 |
32 |
Incidental detection (screening for lung lesion) |
3 |
Mammary hamartoma |
Nil |
Lumpectomy |
Follow-up data is not available |
| 5 |
40 |
120 |
3 |
Mammary hamartoma |
Nil |
Observation |
Follow-up data is not available |
| 6 |
61 |
120 |
3 |
Myofibroblastoma |
Positive: ER, PR, AR, CD34, desmin; Negative: AE1/AE3, SMA, p63 |
Lumpectomy |
Disease-free at 15 months |
| 7 |
72 |
0.5 |
4c |
Granular cell tumor |
Positive: S100, SOX10, TFE3; Negative: GATA3, ER, PR, HER2 |
Wide local excision |
Disease-free at 7 months |
| 8 |
45 |
3 |
4a |
Diffuse large B cell lymphoma |
Positive: CD45, CD20, BCL2, weak BCL6, MUM1, high Ki67; Negative: CD3, synaptophysin, ER, PR |
Chemotherapy (R-CHOP regimen) |
Progression at 8 months with new lymphadenopathy |
| 9 |
47 |
3 |
4a |
Diffuse large B cell lymphoma |
Positive: CD45, CD20, BCL2, high Ki67 index; Negative: CD3, ER, PR, HER2 |
Chemotherapy (R-CHOP regimen) |
Lost to follow-up |
| 10 |
53 |
3 |
4b |
B-cell Non-Hodgkin lymphoma, low grade |
Positive: CD20, PAX5, BCL2, low Ki67 index; Negative: CD3, CD5 |
Chemotherapy (low-intensity regimen) |
Follow-up data is not available |
| 11 |
53 |
1.5 |
5 |
Plasmacytoma |
Positive: CD138; Negative: CD45, CD56 |
VRd regimen + Tamoxifen |
Very good partial response |
